Skip to main content
. 2022 Aug 19;18(6):514–523. doi: 10.4244/EIJ-D-21-00846

Central illustration. Main outcomes of this landmark analysis of the MITRA-FR trial.

Central illustration

Cumulative rates of recurrent hospitalisations for heart failure (A), and Kaplan-Meier estimates for secondary outcomes in the guideline-directed medical treatment (GDMT) and in the transcatheter mitral valve repair (TMVR) groups between 12 and 24 months after inclusion in the MITRA-FR trial: all-cause death or unplanned heart failure hospitalisation (B), all-cause death (C), and hospitalisation for heart failure (D). CI: confidence interval; HR: hazard ratio; RR: rate ratio